TY - JOUR
T1 - Impact of cannabis-based medicine on Alzheimer’s disease by focusing on the amyloid β-modifications
T2 - A systematic study
AU - Farkhondeh, Tahereh
AU - Khan, Haroon
AU - Aschner, Michael
AU - Samini, Fariborz
AU - Pourbagher-Shahri, Ali M.
AU - Aramjoo, Hamed
AU - Roshanravan, Babak
AU - Hoyte, Christopher
AU - Mehrpour, Omid
AU - Samarghandian, Saeed
N1 - Publisher Copyright:
© 2020 Bentham Science Publishers.
PY - 2020
Y1 - 2020
N2 - Deposition of Amyloid-beta (Aβ) peptide in the brain is the leading source of the onset and progression of Alzheimer’s Disease (AD). Recent studies have suggested that anti-amyloidogenic agents may be a suitable therapeutic strategy for AD. The current review was proposed to address the beneficial effects of cannabis-based drugs for the treatment of AD, focusing primarily on Aβ modifi-cations. Keywords related to AD, Aβ, and cannabis-based on MeSH were identified and were searched in PubMed, Google Scholar, Scopus, Ovid-Medline, and Web of Science from inception un-til 15 March 2020. The full text of identified papers was obtained and assessed based on exclusion and inclusion criteria. The review is based on articles that have focused on AD and the amyloidogenic pathway. A total of 17 studies were identified based on the inclusion criteria; however, nine studies qualified for this systematic review. The maximum and minimum cannabis dosages, mostly CBD and THC in animal studies, were 0.75 and 50 mg/kg, respectively. Cannabis (CBD and THC) was injected for 10 to 21 days. The findings of the 9 articles indicated that cannabis-based drugs might modulate Aβ modifications in several AD models. Our findings establish that cannabis-based drugs inhibited the progression of AD by modulating Aβ modifications.
AB - Deposition of Amyloid-beta (Aβ) peptide in the brain is the leading source of the onset and progression of Alzheimer’s Disease (AD). Recent studies have suggested that anti-amyloidogenic agents may be a suitable therapeutic strategy for AD. The current review was proposed to address the beneficial effects of cannabis-based drugs for the treatment of AD, focusing primarily on Aβ modifi-cations. Keywords related to AD, Aβ, and cannabis-based on MeSH were identified and were searched in PubMed, Google Scholar, Scopus, Ovid-Medline, and Web of Science from inception un-til 15 March 2020. The full text of identified papers was obtained and assessed based on exclusion and inclusion criteria. The review is based on articles that have focused on AD and the amyloidogenic pathway. A total of 17 studies were identified based on the inclusion criteria; however, nine studies qualified for this systematic review. The maximum and minimum cannabis dosages, mostly CBD and THC in animal studies, were 0.75 and 50 mg/kg, respectively. Cannabis (CBD and THC) was injected for 10 to 21 days. The findings of the 9 articles indicated that cannabis-based drugs might modulate Aβ modifications in several AD models. Our findings establish that cannabis-based drugs inhibited the progression of AD by modulating Aβ modifications.
KW - Alzheimer’s disease
KW - Amyloid-beta
KW - Cannabidiol
KW - Cannabinoids
KW - Cannabis
KW - Molecular assays
UR - http://www.scopus.com/inward/record.url?scp=85092512566&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092512566&partnerID=8YFLogxK
U2 - 10.2174/1871527319666200708130745
DO - 10.2174/1871527319666200708130745
M3 - Article
C2 - 32640965
AN - SCOPUS:85092512566
SN - 1871-5273
VL - 19
SP - 334
EP - 343
JO - CNS and Neurological Disorders - Drug Targets
JF - CNS and Neurological Disorders - Drug Targets
IS - 5
ER -